Systemic antisense therapeutics inhibitingDUX4expression improves muscle function in an FSHD mouse model
preprint
OA: closed
Abstract
Aberrant expression of the double homeobox 4 ( DUX4 ) gene in skeletal muscle causes muscle deterioration and weakness in Facioscapulohumeral Muscular Dystrophy (FSHD). Since the presence of a permissive pLAM1 polyadenylation signal is essential for stabilization of DUX4 mRNA and translation of DUX4 protein, disrupting the function of this structure can prevent expression of DUX4. We and others have shown promising results using antisense approaches to reduce DUX4 expression in vitro and in vivo following local intramuscular administration. Our group has developed further the antisense chemistries, and demonstrate here enhanced in vitro antisense efficacy. The optimal chemistry was conjugated to a cell-penetrating moiety, and for the first time in FSHD research has been systemically administered into a double-transgenic mouse model of FSHD. After four weekly treatments, mRNA quantities of DUX4 and target genes were reduced by 50% that led to a 5% increase in muscle mass, a 52% improvement in in situ muscle strength, and reduction of muscle fibrosis by 17%. Systemic DUX4 inhibition also improved the locomotor activity significantly and reduced the fatigue level by 22%. Our data overall demonstrate that the optimized antisense approach can contribute to future development of a therapeutic strategy for FSHD.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (59)
- doi:10.1007/s11910-015-0601-x via crossref
- doi:10.1016/j.ncl.2014.04.003 via crossref
- doi:10.1016/s0092-8674(02)00826-7 via crossref
- doi:10.1038/nature04422 via crossref
- doi:10.1016/j.expneurol.2008.07.022 via crossref
- doi:10.1038/ng.2454 via crossref
- doi:10.1016/j.ajhg.2016.03.013 via crossref
- doi:10.1038/s41467-016-0009-6 via crossref
- doi:10.1073/pnas.0708659104 via crossref
- doi:10.1038/emboj.2008.201 via crossref
- doi:10.1002/ana.22275 via crossref
- doi:10.1093/hmg/dds467 via crossref
- doi:10.1093/hmg/ddv315 via crossref
- doi:10.1093/hmg/5.12.1997 via crossref
- doi:10.1111/cge.13726 via crossref
- doi:10.1126/science.1189044 via crossref
- doi:10.7554/elife.06633 via crossref
- doi:10.1371/journal.pone.0016163 via crossref
- doi:10.1093/hmg/ddt409 via crossref
- doi:10.1038/mt.2012.68 via crossref
- doi:10.1093/hmg/ddw015 via crossref
- doi:10.1007/s00439-017-1813-8 via crossref
- doi:10.1073/pnas.1909649117 via crossref
- doi:10.1016/j.omtn.2016.11.009 via crossref
- doi:10.1038/mt.2016.111 via crossref
- doi:10.1016/j.ymthe.2020.10.010 via crossref
- doi:10.1371/journal.pone.0192657 via crossref
- doi:10.1016/j.ajpath.2012.07.007 via crossref
- doi:10.1016/j.devcel.2011.11.013 via crossref
- doi:10.1093/hmg/ddu251 via crossref
- doi:10.1371/journal.pone.0035495 via crossref
- doi:10.1093/hmg/ddaa164 via crossref
- doi:10.1242/jcs.205427 via crossref
- doi:10.1172/jci.insight.123538 via crossref
- doi:10.1016/j.expneurol.2019.113011 via crossref
- doi:10.1126/sciadv.aaw7781 via crossref
- doi:10.1371/journal.pgen.1003529 via crossref
- doi:10.1038/s41598-017-04896-y via crossref
- doi:10.1093/hmg/ddw018 via crossref
- doi:10.1152/physrev.00031.2010 via crossref
- doi:10.1212/con.0000000000000801 via crossref
- doi:10.1113/jphysiol.2007.141481 via crossref
- doi:10.1073/pnas.0604893104 via crossref
- doi:10.2144/000113005 via crossref
- doi:10.1038/mt.2013.263 via crossref
- doi:10.2144/000114167 via crossref
- doi:10.1038/mtna.2014.76 via crossref
- doi:10.1073/pnas.1204638109 via crossref
- doi:10.1093/nar/gkm478 via crossref
- doi:10.1093/hmg/ddn293 via crossref
- doi:10.1038/mtna.2012.30 via crossref
- doi:10.1089/nat.2013.0450 via crossref
- doi:10.1126/science.1104297 via crossref
- doi:10.1038/s41467-016-0009-6 via crossref
- doi:10.1172/jci133303 via crossref
- doi:10.1038/s41598-020-59121-0 via crossref
- doi:10.1093/hmg/dds284 via crossref
- doi:10.1083/jcb.95.3.763 via crossref
- doi:10.1038/mt.2010.261 via crossref
Source provenance
- crossref
- last seen: 2026-06-17T06:32:12.311806+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-07-15T06:44:59.916582+00:00